INT241861

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.17
First Reported 2007
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 7
Total Number 8
Disease Relevance 7.23
Pain Relevance 1.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (EPCAM)
Anatomy Link Frequency
bladder 1
EPCAM (Homo sapiens)
Pain Link Frequency Relevance Heat
narcan 5 99.84 Very High Very High Very High
Inflammation 33 99.48 Very High Very High Very High
Opioid 2 98.36 Very High Very High Very High
Morphine 2 83.20 Quite High
agonist 3 74.96 Quite High
opioid receptor 3 74.64 Quite High
palliative 10 73.20 Quite High
qutenza 2 72.08 Quite High
Endogenous opioid 3 62.72 Quite High
Enkephalin 2 56.16 Quite High
Disease Link Frequency Relevance Heat
Cancer 351 99.98 Very High Very High Very High
Lymphatic System Cancer 115 99.56 Very High Very High Very High
INFLAMMATION 34 99.48 Very High Very High Very High
Anaemia 539 99.44 Very High Very High Very High
Bladder Cancer 10 98.36 Very High Very High Very High
Solid Tumor 25 97.68 Very High Very High Very High
Injury 3 95.96 Very High Very High Very High
Chronic Lymphoid Leukemia 15 83.44 Quite High
Pressure And Volume Under Development 29 82.44 Quite High
Chronic Renal Failure 22 78.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, some investigators showed that anti-inflammatory effects of low frequency ESA were not affected by naloxone (31), suggesting that a non-opioid mechanism may be involved in anti-inflammatory effect by low frequency ESA.
Neg (not) Regulation (affected) of ESA associated with inflammation, narcan and opioid
1) Confidence 0.17 Published 2007 Journal Journal of Korean Medical Science Section Body Doc Link PMC2693606 Disease Relevance 1.29 Pain Relevance 1.15
A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients

Purpose

Regulation (targeting) of EpCAM in bladder associated with bladder cancer
2) Confidence 0.12 Published 2010 Journal Drug Design, Development and Therapy Section Title Doc Link PMC2998804 Disease Relevance 0.45 Pain Relevance 0
Efficacy of ESA treatment in lymphoma and myeloma patients
Regulation (Efficacy) of ESA associated with lymphatic system cancer
3) Confidence 0.12 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504072 Disease Relevance 1.43 Pain Relevance 0
However, in spite of these reports, meta-analyses fail to show an improved survival or tumor control in ESA-treated patients in randomized studies (Bohlius et al 2006a), and no larger single study has shown a significant survival advantage.
Regulation (control) of ESA associated with cancer
4) Confidence 0.09 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504072 Disease Relevance 0.69 Pain Relevance 0
Effectiveness of ESA treatment in lymphoma and myeloma
Regulation (Effectiveness) of ESA associated with lymphatic system cancer
5) Confidence 0.09 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504072 Disease Relevance 0.92 Pain Relevance 0.07
QoL has been studied in a large number of ESA treatment studies in cancer and the results have constantly been positive for ESA treatment.
Regulation (positive) of ESA associated with cancer
6) Confidence 0.09 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504072 Disease Relevance 0.88 Pain Relevance 0
Response to ESA therapy has generally been defined as an increase in Hb of >2 g/dl, and response rates vary between investigations, depending on the profile of the study populations.
Spec (investigations) Regulation (Response) of ESA
7) Confidence 0.09 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504072 Disease Relevance 1.23 Pain Relevance 0
A hemoglobin value above or below this range will trigger a change in the ESA dose.
Regulation (change) of ESA
8) Confidence 0.04 Published 2010 Journal Trials Section Body Doc Link PMC2903576 Disease Relevance 0.33 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox